Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)’s share price rose 5.7% during trading on Friday . The company traded as high as $3.41 and last traded at $3.35, with a volume of 103,137 shares traded. The stock had previously closed at $3.17.

DRNA has been the subject of a number of analyst reports. Chardan Capital reaffirmed a “neutral” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, April 14th. Stifel Nicolaus reduced their price objective on shares of Dicerna Pharmaceuticals from $16.00 to $13.00 and set a “buy” rating for the company in a report on Thursday, June 30th. Jefferies Group reaffirmed a “buy” rating and set a $19.00 price objective on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Cowen and Company reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Tuesday, May 10th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Dicerna Pharmaceuticals in a report on Thursday, June 30th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $11.95.

The stock has a 50 day moving average price of $3.42 and a 200 day moving average price of $5.19. The stock’s market capitalization is $70.47 million.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its earnings results on Monday, May 9th. The biopharmaceutical company reported ($0.76) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.86) by $0.10. On average, equities analysts expect that Dicerna Pharmaceuticals Inc. will post ($3.34) earnings per share for the current fiscal year.

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.